Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Severe Combined Immunodeficiency 1Neuroblastoma 1Neoplasms 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1

Interventions

trametinib 2dabrafenib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2ulixertinib 1trastuzumab biosimilar HLX02 1thymoglobulin 1temsirolimus 1sapanisertib 1ropidoxuridine 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entrectinib 1defactinib 1copanlisib 1cobimetinib 1ceritinib 1cc-486 1capmatinib 1capivasertib 1bintrafusp alfa protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Prospective Studies × CNS × Clear all
NCT00695279 2024-10-30

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

St. Jude Children's Research Hospital

Completed
41 enrolled
CNSOther hematologic neoplasm

Mucopolysaccharidosis I, Neoplasms, Neuroblastoma, Severe Combined Immunodeficiency, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡